CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up
Zacks Investment Research | Aug 29, 2016 10:05PM ET
CTI BioPharma Corp.’s (NASDAQ:CTIC) shares gained 14.9% after the company announced top-line results from a phase III study (PERSIST-2) on pacritinib, wherein the study met one of the co-primary endpoints.
The PERSIST-2 study evaluated pacritinib in comparison to the best available therapy (BAT (LON:BATS)), including Incyte Corporation’s (NASDAQ:INCY) Jakafi (ruxolitinib), for the treatment of myelofibrosis in patients whose platelet counts were less than 100,000 per microliter.
Results from the study demonstrated a statistically significant improvement in spleen volume reduction (SVR) in patients treated with pacritinib, thereby meeting one of the co-primary endpoints. Although the study failed to meet the co-primary endpoint of greater than 50% reduction in Total Symptom Score (TSS), its preliminary analysis approached marginal significance in comparison with BAT.
The most common adverse events associated with pacritinib were diarrhea, nausea and vomiting, which were found to be generally manageable.
CTI BIOPHARMA Price
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.